This project is proudly led internally by A Biotech Company, supported by the SyBiCITE programme at Imperial College London and the UKRI. This prestigious support reflects both the scientific merit and the transformative potential of this project to be carried out in collaboration with UCL Department of Biochemical Engineering and the Institute of Child Health.

Our mission is to harness the therapeutic potential of extracellular vesicles as payload delivery carriers, opening new avenues in cancer therapy. By focusing on these naturally occurring, cell-derived particles, we aim to develop novel treatments that enhance precision, efficacy, and safety for cancer patients. We embark on this pioneering journey aimed at revolutionising cancer care, turning groundbreaking science into life-changing therapies.

Extracellular vesicles are lipid bilayer nanoparticles naturally secreted by almost all cell types, playing a critical role in cell-to-cell communication by transporting bioactive compounds. Our proprietary technology is built on a groundbreaking platform that redefines how extracellular vesicles are produced, packaged, and tailored for each and specific therapeutic function - unlocking new possibilities in precision medicine.

Immune cell-derived extracellular vesicles, such as those produced from T cells hold enormous promise as cell-free therapeutics. They capture the functional essence of their parent cells, including anti-tumour activity, immune regulation, or tissue repair yet without the challenges and risks associated with full cell therapies.

Through genetic engineering of parent cells, extracellular vesicles can further be tailored to carry specific molecules, signals, or even therapeutic payloads. This opens the door to highly customised EV therapies, from cancer-targeting EVs that treat tumours with the delivery of drugs, to engineered EVs carrying regenerative signals for damaged tissues, or even EVs designed to cross the blood–brain barrier for neurological applications. In this way, EVs act as living nanomedicines, programmable and adaptable to future needs.

By pursuing this project, A Biotech Company aims to answer critical questions: How can EVs be produced at scale and with consistency? What are the key markers of therapeutic potency? How can we ensure safety, targeting, and functionality across different patient populations? Addressing these questions is the foundation of an entirely new therapeutic modality.

Such therapeutics could overcome the limitations of existing treatments, reducing costs, improving accessibility, and enabling therapies in environments where complex cell-manufacturing is not feasible (including in space or remote healthcare). This project reimagines what is possible in drug delivery and regenerative medicine.

Through SyBiCITE and UKRI’s support, this work positions A Biotech Company at the forefront of a new biotherapeutic era, one where immune cell-derived extracellular vesicles redefine what medicine looks like: precise, programmable, and profoundly more accessible.